Trials / Active Not Recruiting
Active Not RecruitingNCT04403139
VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- University of Washington · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells
Detailed description
This is an interventional study of vaccination related to infection with varicella zoster virus. We will enroll participants of two age groups. Cohort 1 will be persons between the ages of 30-40; Cohort 2 will be persons who are 70 years of age or older. All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Shingrix | All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule. |
Timeline
- Start date
- 2022-04-27
- Primary completion
- 2026-02-01
- Completion
- 2026-02-01
- First posted
- 2020-05-27
- Last updated
- 2025-04-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04403139. Inclusion in this directory is not an endorsement.